A Study of Ruxolitinib in Patients With Graft-Versus Host Disease

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

NCT07012304 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

NCT07184853 ·Status: RECRUITING ·Phase: NA

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

NCT06462469 ·Status: RECRUITING ·Phase: PHASE4

Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis

NCT07440654 ·Status: NOT_YET_RECRUITING ·Phase: NA

Itacitinib for Low Risk GVHD

NCT03846479 ·Status: COMPLETED ·Phase: PHASE2

Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

NCT07509749 ·Status: RECRUITING ·Phase: PHASE2

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

NCT05121142 ·Status: COMPLETED ·Phase: PHASE1

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

NCT04971551 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

NCT07366801 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Ruxolitinib for Steroid-refractory GVHD

NCT02997280 ·Status: COMPLETED ·Phase: PHASE2

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02759731 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

NCT06824103 ·Status: RECRUITING ·Phase: PHASE4

Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

NCT03774082 ·Status: COMPLETED ·Phase: PHASE2

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

NCT07340723 ·Status: RECRUITING ·Phase: PHASE2

Tocilizumab for Chronic Graft-versus-Host Disease Treatment

NCT02174263 ·Status: WITHDRAWN ·Phase: PHASE2

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

NCT06695507 ·Status: TERMINATED ·Phase: PHASE1

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

NCT03491215 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

First Line Therapy for High Risk Acute GVHD

NCT04061876 ·Status: COMPLETED ·Phase: PHASE2

A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)

NCT01066598 ·Status: TERMINATED ·Phase: PHASE2

A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation

NCT07381114 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Rituximab for GVHD

NCT00578591 ·Status: WITHDRAWN ·Phase: PHASE2

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT06660355 ·Status: RECRUITING ·Phase: PHASE2

Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host Disease

NCT04448587 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078 ·Status: RECRUITING ·Phase: PHASE2

Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

NCT03395340 ·Status: TERMINATED ·Phase: PHASE2